First AD

Second AD

Data from the following clinical trials are discussed:

620: Three-Year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

333: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

 Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

The Talk

® The TALK features a group of subject matter experts discussing key datasets and exciting updates from recent oncology conferences in various cancer types. These video programs are designed to highlight important areas of research and hot topics in the field of breast cancer, lung cancer, and multiple myeloma, among specialties. 

Leukemia: A Review of Data from the ASH 2022 Meeting

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Cleveland Clinic

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

ASH 2022: Recent Advances in Chronic Myeloid Leukemia